市場調査レポート

世界の統合失調症の発症率・企業分析・薬剤予測(2010-2015年)

Global Schizophrenia Prevalence, Companies Analysis & Drugs Forecast, 2010-2015

発行 Renub Research 商品コード 208006
出版日 ページ情報 英文 65 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=102.95円で換算しております。
Back to Top
世界の統合失調症の発症率・企業分析・薬剤予測(2010-2015年) Global Schizophrenia Prevalence, Companies Analysis & Drugs Forecast, 2010-2015
出版日: 2011年08月10日 ページ情報: 英文 65 Pages
概要

現在、実に多くの統合失調症治療薬が市場に出回っています。Zyprexa、Seroquel、Risperdal、Abilify、Geodonなどが市場のダイナミクスを変えたブロックバスター薬としてあげられますが、主要ブロックバスターのほとんどは2011年から2012年にかけて特許が失効するため、これが製造業者の懸念材料となっています。

当レポートでは、世界の統合失調症市場について調査分析し、主要国における現在の罹患人口と今後の見通し、主要治療薬ブランド、主要デポ剤の売上実績・予測、パイプライン薬の展望、主要企業のプロファイルなどをまとめ、概略以下の構成でお届けいたします。

第1章 エグゼクティブサマリー

第2章 世界の統合失調症市場:過去・現在・未来の動向

第3章 主要7ヵ国の発症動向

  • 米国
    • 統合失調症の罹患人口・将来のシナリオ
  • 日本
    • 統合失調症の罹患人口・将来のシナリオ
  • ドイツ
    • 統合失調症の罹患人口・将来のシナリオ
  • フランス
    • 統合失調症の罹患人口・将来のシナリオ
  • イタリア
    • 統合失調症の罹患人口・将来のシナリオ
  • 英国
    • 統合失調症の罹患人口・将来のシナリオ
  • スペイン
    • 統合失調症の罹患人口・将来のシナリオ

第4章 世界の統合失調症治療薬:市場実績トップ10ブランド

  • Zyprexa (Olanzapine)
  • Seroquel (Quetiapine)
  • Geodon
  • Risperdal (Risperidone)
  • Lonasen
  • Serdolect
  • Abilify (Aripiprazole)
  • Invega (Paliperidone)
  • Fanapt (iloperidone)
  • Saphris (Asenapine)

第5章 世界の統合失調症デポ剤:市場実績トップ3ブランド

  • Risperdal Consta (Risperidone)
  • Invega Sustenna (Paliperidone Palmitate)
  • Relprevv/Zyphdera (Olanzapine LAI)

第6章 パイプライン薬:将来動向

  • Lurasidone
  • Staccato (Loxapine Inhalation)
  • Cariprazine (RGH-188)
  • Pimavanserin

第7章 主要企業

  • Eli Lilly and Company
    • 事業概要
    • 強み・弱み
  • Astrazeneca
    • 事業概要
    • 強み・弱み
  • Johnson & Johnson
    • 事業概要
    • 強み・弱み
  • Bristol-Myers Squibb
    • 事業概要
    • 強み・弱み
  • Pfizer
    • 事業概要
    • 強み・弱み

図表

目次

Schizophrenia is a mental disorder characterized by disintegration of thought processes and of emotional responsiveness. It most commonly manifests as auditory hallucinations, paranoid or bizarre delusions, or disorganized speech and thinking, or lack of concentration and motivation and it is accompanied by significant social or occupational dysfunction. However with proper medication this disease can be contained to a great extent and Schizophrenia patients can lead a normal healthy life style.

At present lot of drugs for Schizophrenia are available in the market. From the introduction of Clozapine in 1991.Since, 1960, the first atypical antipsychotic to treat schizophrenia, the growth of this class has been rapid. Zyprexa, Seroquel, Risperdal, Abilify, Geodon are the blockbuster drug which has changed the dynamics of the schizophrenia market. But the major worry for the manufactures of these drugs is that by 2011 and 2012 almost all the major blockbuster drugs are going off-patent.

However, depot formulation is the emerging segment which has long term chances of success. The pipeline drug like Lurasidone, Staccato, Cariprazine, Pimavanserin have the comparable efficacy and a similar mechanism of action to that of the existing brands which will enter the market by 2011.

Report Details

“Global Schizophrenia Prevalence, Companies Analysis & Drugs Forecast (2010 - 2015)” report published by Renub Research provides an in-depth analysis of the past, present and future prospects. The report has been researched at source globally and features latest available data covering:

  • Global Schizophrenia Market has been covered from 2004-2019
  • Global Schizophrenia patients in 7 countries
  • Top 10 Schizophrenia Drug Brands (Zyprexa, Seroquel, Risperdal, Abilify, Geodon, Lonasen, Serdolect, Invega, Fanapt, Saphris) data analysis of Past, Present and Future Market
  • Top 3 Schizophrenia Depot Formulations Brands (Risperdal Consta, Invega Sustenna, Relprevv) data analysis of Past, Present and Future Market
  • Pipeline Developmental Agents (Lurasidone, Staccato, Cariprazine, Pimavanserin) Future Trends Analyis
  • Key Companies Strengths and Weakness analysis in Global Schizophrenia

Research Highlights

  • The prevalence of Schizophrenia in United States is expected to reach nearly 4 Million by 2020
  • From 2012 onwards Schizophrenia market is expected to show a decline
  • Zyprexa is the most successful product in the history of neuroscience
  • Abilify hit blockbuster sales in 2006 and it is anticipated that sales will cross US$ 2.5 Billion by 2014.
  • Risperdal Consta is the blockbuster injectable form of medicines and predicted that the sale will cross US$ 2 Billion by 2014
  • Lurasidone, Staccato, Cariprazine, Pimavanserin are the pipepline drug which will be launched by 2011

Key Companies Analyzed

This section covers the business description, Strengths and Weakness of major players in Global Schizophrenia Market. The key players analyzed in this section are - Eli Lilly and Company, AstraZeneca, Johnson & Johnson, Bristol-Myers Squibb and Pfizer.

Data Sources

Information and data in this report has been collected from various printable and non-printable sources like Trade Journals, White papers, Online paid databases, News websites, Government Agencies, Magazines, Newspapers and Trade associations.

Table of Contents

1. Executive Summary

2. Global Schizophrenia Market Past, Present & Future Trend

3. Prevalence of Schizophrenia in Top 7 Countries

  • 3.1. United States of America
    • 3.1.1. Schizophrenia Population & Future Scenario
  • 3.2. Japan
    • 3.2.1. Schizophrenia Population & Future Scenario
  • 3.3. Germany
    • 3.3.1. Schizophrenia Population & Future Scenario
  • 3.4. France
    • 3.4.1. Schizophrenia Population & Future Scenario
  • 3.5. Italy
    • 3.5.1. Schizophrenia Population & Future Scenario
  • 3.6. United Kingdom
    • 3.6.1. Schizophrenia Population & Future Scenario
  • 3.7. Spain
    • 3.7.1. Schizophrenia Population & Future Scenario

4. Global - Top 10 Schizophrenia Drug Brands Market Performance

  • 4.1. Zyprexa (Olanzapine)
  • 4.2. Seroquel (Quetiapine)
  • 4.3. Geodon
  • 4.4. Risperdal (Risperidone)
  • 4.5. Lonasen
  • 4.6. Serdolect
  • 4.7. Abilify (Aripiprazole)
  • 4.8. Invega (Paliperidone)
  • 4.9. Fanapt (iloperidone)
  • 4.10. Saphris (Asenapine)

5. Global - Top 3 Schizophrenia Depot Formulations Brand Market Performance

  • 5.1. Risperdal Consta (Risperidone)
  • 5.2. Invega Sustenna (Paliperidone Palmitate)
  • 5.3. Relprevv/Zyphdera (Olanzapine LAI)

6. Pipeline Developmental Agents - Future Trends

  • 6.1. Lurasidone
  • 6.2. Staccato (Loxapine Inhalation)
  • 6.3. Cariprazine (RGH-188)
  • 6.4. Pimavanserin

7. Key Companies

  • 7.1. Eli Lilly and Company
    • 7.1.1. Business Description
    • 7.1.2. Strength & Weaknesses
  • 7.2. Astrazeneca
    • 7.2.1. Business Description
    • 7.2.2. Strength & Weaknesses
  • 7.3. Johnson & Johnson
    • 7.3.1. Business Description
    • 7.3.2. Strength & Weaknesses
  • 7.4. Bristol-Myers Squibb
    • 7.4.1. Business Description
    • 7.4.2. Strength & Weaknesses
  • 7.5. Pfizer
    • 7.5.1. Business Description
    • 7.5.2. Strength & Weaknesses

List of Figure:

  • Figure 2 1: Global - Schizophrenia Market (Billion US$), 2004 - 2010
  • Figure 2 2: Global - Forecast for Schizophrenia Market (Billion US$), 2011 - 2019
  • Figure 3 1: USA - Number of Patients with Schizophrenia Disease (Million), 2005 - 2010
  • Figure 3 2: Japan - Number of Patients with Schizophrenia Disease (Million), 2005 - 2010
  • Figure 3 3: Germany - Number of Patients with Schizophrenia Disease (Million), 2005 - 2010
  • Figure 3 4: France - Number of Patients with Schizophrenia Disease (Million), 2005 - 2010
  • Figure 3 5: Italy - Number of Patients with Schizophrenia Disease (Million), 2005 - 2010
  • Figure 3 6: UK - Number of Patients with Schizophrenia Disease (Million), 2005 - 2010
  • Figure 3 7: Spain - Number of Patients with Schizophrenia Disease (Million), 2005 - 2010
  • Figure 4 1: Global - Zyprexa Drug Sales (Million US$), 1999 - 2010
  • Figure 4 2: Global - Forecast for Zyprexa Drug Sales (Million US$), 2011 - 2015
  • Figure 4 3: Global - Seroquel Drug Sales (Million US$), 1999 - 2010
  • Figure 4 4: Global - Forecast for Seroquel Drug Sales (Million US$), 2011 - 2015
  • Figure 4 5: Global - Geodon Drug Sales (Million US$), 1999 - 2010
  • Figure 4 6: Global - Forecast for Geodon Drug Sales (Million US$), 2011 - 2015
  • Figure 4 7: Global - Risperdal Drug Sales (Million US$), 1999 - 2010
  • Figure 4 8: Global - Forecast for Risperdal Drug Sales (Million US$), 2011 - 2015
  • Figure 4 9: Global - Lonasen Drug Sales (Million US$), 2008 - 2010
  • Figure 4 10: Global - Forecast for Lonasen Drug Sales (Million US$), 2011 - 2014
  • Figure 4 11: Global - Serdolect Drug Sales (Million US$), 2006 - 2010
  • Figure 4 12: Global - Forecast for Serdolect Drug Sales (Million US$), 2011 - 2015
  • Figure 4 13: Global - Abilify Drug Sales (Million US$), 2002 - 2010
  • Figure 4 14: Global - Forecast for Abilify Drug Sales (Million US$), Q1-2011, 2011 - 2015
  • Figure 4 15: Global - Invega Drug Sales (Million US$), 2008 - 2010
  • Figure 4 16: Global - Forecast for Invega Drug Sales (Million US$), 2011 - 2015
  • Figure 4 17: Global - Forecast for Fanapt Drug Sales (Million US$), 2011 - 2015
  • Figure 4 18: Global - Forecast for Saphris Drug Sales (Million US$), 2011 - 2015
  • Figure 5 1: Global - Risperdal Consta Drug Sales (Million US$), 2006 - 2010
  • Figure 5 2: Global - Forecast for Risperdal Consta Drug Sales (Million US$), 2011 - 2015
  • Figure 5 3: Global - Invega Sustenna Drug Sales (Million US$), 2009 - 2010
  • Figure 5 4: Global - Forecast for Invega Sustenna Drug Sales (Million US$), 2011 - 2015
  • Figure 5 5: Global - Relprevv/Zyphdera Drug Sales (Million US$), 2009 - 2010
  • Figure 5 6: Global - Forecast for Relprevv/Zyphdera Drug Sales (Million US$), 2011 - 2015
  • Figure 6 1: Global - Forecast for Lurasidone Drug Sales (Million US$), 2011 - 2017
  • Figure 6 2: Global - Forecast for Staccato Drug Sales (Million US$), 2010 - 2017
  • Figure 6 3: Global - Forecast for Cariprazine Drug Sales (Million US$), 2013 - 2017
  • Figure 6 4: Global - Forecast for Pimavanserin Drug Sales (Million US$), 2014 - 2017

List of Tables:

  • Table 3 1: USA - Forecast for Number of Patients with Schizophrenia Disease (Million), 2010 - 2015, 2020, 2025, 2030, 2035, 2040, 2045, 2050
  • Table 3 2: Japan - Forecast for Number of Patients with Schizophrenia Disease (Million), 2010 - 2015, 2020, 2025, 2030, 2035, 2040, 2045, 2050
  • Table 3 3: Germany - Forecast for Number of Patients with Schizophrenia Disease (Million), 2011 - 2015, 2020, 2025, 2030, 2035, 2040, 2045, 2050
  • Table 3 4: France - Forecast for Number of Patients with Schizophrenia Disease (Million), 2011 - 2015, 2020, 2025, 2030, 2035, 2040, 2045, 2050
  • Table 3 5: Italy - Forecast for Number of Patients with Schizophrenia Disease (Million), 2011 - 2015, 2020, 2025, 2030, 2035, 2040, 2045, 2050
  • Table 3 6: UK - Forecast for Number of Patients with Schizophrenia Disease (Million), 2010 - 2015, 2020, 2025, 2030, 2035, 2040, 2045, 2050
  • Table 3 7: Spain - Forecast for Number of Patients with Schizophrenia Disease (Million), 2011 - 2015, 2020, 2025, 2030, 2035, 2040, 2045, 2050
  • Table 4 1: Eli Lilly - Challenges to Zyprexa Patents in a number of Countries outside the U.S (2007, 2008 & 2010)
  • Table 7 1: Eli Lilly and Company - Key Financial (Million US$), 2008 - 2010
  • Table 7 2: Astrazeneca - Key Financial (Million US$), 2008 - 2010
  • Table 7 3: Johnson & Johnson - Key Financial (Million US$) 2008 - 2010
  • Table 7 4: Bristol-Myers Squibb - Key Financial (Million US$) 2008 - 2010
  • Table 7 5: Global - Comparison Chart of Patent Expiry Date of different Blockbuster Drugs
  • Table 7 6: Pfizer - Key Financial (Million US$), 2008 - 2010
Back to Top